Skip to main content
Signal8

BioLineRx Ltd. (BLRX) Form 6-K — Nov 16, 2026

$BLRXForm 6-KFiled Nov 16, 2026, 7:08 AM ET0001178913-26-005231Original filing

BioLineRx and partner Hemispherian presented two posters on GLIX1 at the 31st Society for Neuro-Oncology Annual Meeting, showing robust, dose-dependent antitumor activity across multiple glioblastoma models, including tumor eradication in the SNB19 CDX model and activity in a temozolomide-resistant PDX model where TMZ was ineffective. New preclinical PK/PD data demonstrated confirmed brain penetration at all tested dose levels and dose-dependent increases in tumor 5hmC, a marker of GLIX1's TET2-activating mechanism, correlating with tumor growth inhibition.

Key figures

Current cohort
4
Clinical trial id
NCT07464925
Data readout timing
first half of 2027

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.